Book Value per Share: Neumora Therapeutics (NMRA)

Neumora Therapeutics (NMRA) - corporate logo

Neumora Therapeutics (NMRA) is a biopharmaceutical innovator developing precision CNS treatments powered by big data analytics. This daily price action reflects a market dynamic currently fixed at 0.24. The company is currently focused on clinical trials, utilizing internal reserves due to a lack of regular profits. Product commercialization is hindered by stringent insurance requirements, which temporarily deprives the company of its pricing power.

Neumora (NMRA) Equity per Share: for the period 02/21/2024 - 10/28/2026

neumoratx.com - analytical breakdowns and key metrics (NMRA)

- price and consensus price forecast:
Price Chart Neumora Therapeutics Inc|NMRA - Fair Value Consensus
- market capitalization data:
Market Capitalization Neumora Therapeutics, Inc.|NMRA - Enterprise Value
- book capitalization data:
Net Assets per Single Share Neumora Therapeutics|NMRA - Accounting Capitalization|Market Capitalization to Book Value Ratio neumoratx.com|NMRA - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Neumora Therapeutics|NMRA - Long-Term Debt to Capital|Short-Term Debt to Equity Neumora Therapeutics, Inc.|NMRA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Neumora Therapeutics, Inc.|NMRA - Long-Term Debt|Company Short-Term Debt Neumora Therapeutics
Fundamental company valuation:Neumora Therapeutics Inc, NMRA
Manufactured products of Neumora Therapeutics, Inc.

The BVPS valuation analysis reflects the status of Neumora Therapeutics (NMRA) as a biotech issuer whose value is based on the capital deployed in the development of drugs for depression and schizophrenia. This indicator is calculated as the difference between all assets and liabilities divided by the number of shares, allowing an investor to assess the intrinsic value of the business and the resilience of its financial foundation against market volatility.

Competitor analysis for Neumora Therapeutics

Net Assets per Single Share Biogen Corp (BIIB)|NBIX - Accounting Value of a Share|RGC: Book Value per Share|AXSM (axsome.com) - Book Value per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|TRVI (Trevi Corp) - Net Asset Value per Share|Net Assets per Single Share Praxis Precision Medicines (PRAX)|Equity per Share anavex.com|CeriBell - Book Value per Share|Net Asset Value per Share Prothena Corporation PRTA|Accounting Value per Share ALEC (Alector)|Annexon Biosciences Inc. - Book Value per Share|OMER: Net Assets per Single Share|NGNE: Accounting Value per Share|Net Assets per Single Share ACIU|VYGR (Voyager Therapeutics Inc) - Net Asset Value per Share|SCLX - Net Assets per Single Share|Accounting Value of a Share Tevogen Bio Inc.|Book Value per Share ACOG|Book Value per Share Cognition Therapeutics Inc. CGTX|Accounting Value per Share Inhibikase Therapeutics, Inc.|SAVA - Accounting Value of a Share|Accounting Value per Share Assertio Therapeutics ASRT|COYA - Book Price of a Share|Book Value per Share vistagen.com VTGN|Ovid Therapeutics (OVID) - Accounting Value of a Share|Book Value per Share ABOS (Acumen Pharmaceuticals, Inc.)|Net Asset Value per Share CRVO|Alterity Therapeutics (ATHE) - Net Assets per Single Share|Accounting Value of a Share clene.com (CLNN)|Book Value per Share PEPG (PepGen)|Jupiter Neurosciences, Inc. - Book Value per Share|Net Assets per Single Share Relmada Therapeutics, Inc.|ANVS - Share Book Value|Book Value per Share GRCE|Net Asset Value per Share Firefly Neuro|KLTO (ANEW Medical) - Accounting Value per Share|Book Value per Share NeuroSense Therapeutics, Ltd. (NRSN)|Accounting Value per Share Reviva Pharmaceuticals Holdings, Inc.|Book Price of a Share metaviatx.com (MTVA)|Book Value per Share NRXS|Net Assets per Share Helius Medical Technologies, Inc. HSDT|PASG: Book Value per Share|NEUP: Accounting Value per Share|Minerva Neurosciences, Inc. - Net Assets per Single Share|ATHA (Athira Pharma Inc) - Net Assets per Share|Net Assets per Single Share Addex Therapeutics, Ltd. (ADXN)|Equity per Share ALZN|Net Assets per Single Share CYCN (Cyclerion Therapeutics)|Accounting Value per Share PTIX (protagenic.com)|Net Assets per Single Share Pasithea Therapeutics Corp.|Accounting Value of a Share Cortigent Inc CRGT|Avenue Therapeutics, Inc - Book Value per Share|BCLI: Book Value per Share|Net Assets per Single Share Cara Therapeutics, Inc.|chromocell.com (CHRO) - Equity per Share|Book Value per Share ELYM (Eliem Therapeutics, Inc.)|Net Asset Value per Share Intra-Cellular (ITCI)|Accounting Value per Share LBPH|Book Value per Share MRNS (Marinus Pharma)|Net Assets per Single Share NKGen Biotech, Inc.|neurobopharma.com - Accounting Value of a Share|SAGE (Sage Therapeutics) - Net Assets per Single Share|SNPX: Net Asset Value per Share|Net Assets per Single Share Trevena, Inc|Vigil Neuroscience, Inc. (VIGL) - Equity per Share|Book Value per Share WENA (Anew Medical)|Net Asset Value per Share cerevel.com (CERE)